



Description générale

A fixed-dose combination regimen of the direct acting antiviral agents sofosbuvir and velpatasvir for the treatment of genotypes 1-6 chronic hepatitis C virus (HCV) infection.

INN	Sofosbuvir + velpatasvir
Codes ATC	J05AP55
Type de médicament	Chemical agent
Historique des statuts LME	Ajouté pour la première fois en 2017 (TRS 1006) pour Chronic hepatitis C
Wikipédia	Sofosbuvir + velpatasvir ↗
DrugBank	Sofosbuvir ↗ Velpatasvir ↗

Recommandations

Section Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg

Indications

Chronic hepatitis C

